Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck
EEW Cohen, F Rosen, WM Stadler… - Journal of clinical …, 2003 - ascopubs.org
Purpose: The epidermal growth factor receptor (EGFR) is a mediator of squamous cell
carcinoma of the head and neck (SCCHN) development. ZD1839 is an orally active …
carcinoma of the head and neck (SCCHN) development. ZD1839 is an orally active …
ZD1839, a selective oral epidermal growth factor receptor–tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a …
M Ranson, LA Hammond, D Ferry, M Kris… - Journal of Clinical …, 2002 - ascopubs.org
PURPOSE: To investigate the tolerability, pharmacokinetics, and antitumor activity of the
oral, selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 in patients …
oral, selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 in patients …
Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five …
J Baselga, D Rischin, M Ranson, H Calvert… - Journal of clinical …, 2002 - ascopubs.org
PURPOSE: To establish the safety and tolerability of ZD1839 (Iressa), a selective epidermal
growth factor receptor (EGFR) tyrosine kinase inhibitor, and to explore its pharmacokinetic …
growth factor receptor (EGFR) tyrosine kinase inhibitor, and to explore its pharmacokinetic …
Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non–small-cell lung cancer and other …
RS Herbst, AM Maddox, ML Rothenberg… - Journal of Clinical …, 2002 - ascopubs.org
PURPOSE: To investigate safety, tolerability, dose-related pharmacologic properties, and
pharmacodynamics of ZD1839 (gefinitib, Iressa; AstraZeneca Pharmacueticals, Wilmington …
pharmacodynamics of ZD1839 (gefinitib, Iressa; AstraZeneca Pharmacueticals, Wilmington …
Sequence-dependent effects of ZD1839 ('Iressa') in combination with cytotoxic treatment in human head and neck cancer
N Magne, JL Fischel, A Dubreuil, P Formento… - British journal of …, 2002 - nature.com
Elevated levels of epidermal growth factor receptor in head and neck cancer have been
extensively reported, and are correlated with poor prognosis. The combination of cisplatin …
extensively reported, and are correlated with poor prognosis. The combination of cisplatin …
Pharmacodynamic studies with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839
J Albanell, F Rojo, J Baselga - Seminars in oncology, 2001 - Elsevier
ZD1839 is an orally active, selective epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitor that blocks signal transduction pathways implicated in the proliferation and …
kinase inhibitor that blocks signal transduction pathways implicated in the proliferation and …
Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of …
J Albanell, F Rojo, S Averbuch… - Journal of Clinical …, 2002 - ascopubs.org
PURPOSE: The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839
(Iressa; AstraZeneca Pharmaceuticals, Alderley Park, United Kingdom) is under …
(Iressa; AstraZeneca Pharmaceuticals, Alderley Park, United Kingdom) is under …
Modulation of radiation response and tumor-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 (Iressa)
SM Huang, J Li, EA Armstrong, PM Harari - Cancer research, 2002 - AACR
Abstract ZD1839 (“Iressa”) is an orally-active, selective epidermal growth factor receptor-
tyrosinekinase inhibitor. We evaluated the antitumor activity of ZD1839 in combination with …
tyrosinekinase inhibitor. We evaluated the antitumor activity of ZD1839 in combination with …
Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of …
D Soulieres, NN Senzer, EE Vokes… - Journal of clinical …, 2004 - ascopubs.org
Purpose To determine the efficacy and safety profiles of erlotinib in patients with advanced
recurrent and/or metastatic squamous cell cancer of the head and neck (HNSCC). Patients …
recurrent and/or metastatic squamous cell cancer of the head and neck (HNSCC). Patients …
Pharmacokinetics and tolerability of the orally active selective epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in healthy volunteers
H Swaisland, A Laight, L Stafford, H Jones… - Clinical …, 2001 - Springer
Objective: To investigate the pharmacokinetics and tolerability of ZD1839 (Iressa™), an
orally active selective epidermal growth factor receptor-tyrosine kinase inhibitor, in healthy …
orally active selective epidermal growth factor receptor-tyrosine kinase inhibitor, in healthy …